9,11-Dehydrocortexolone 17α-butyrate
9,11-Dehydrocortexolone 17α-butyrate (developmental code name CB-03-04) is a synthetic steroidal antiandrogen that was developed for use as a topical medication but was never marketed.[1] It is the C17α butyrate (butanoate) ester of the 9,11-dehydrogenated analogue of 11-deoxycortisol (cortexolone).[1] C17α esters of 11-deoxycortisol were unexpectedly found to possess antiandrogen activity, and 9,11-dehydrocortexolone 17α-butyrate was selected for development based on its optimum drug profile.[1] In rats, the drug has been found to possess strong local antiandrogen activity and to also be active systemically upon subcutaneous injection.[1] In addition, it has been found to possess antigonadotropic activity.[1] In terms of topical antiandrogen potency, 9,11-dehydrocortexolone 17α-butyrate was found to be more potent than flutamide and finasteride and less than or equal to cyproterone acetate in potency.[1] The drug has been suggested for possible development and medical use for the treatment of prostate cancer and benign prostatic hyperplasia.[1]
![]() | |
Clinical data | |
---|---|
Other names | CB-03-04; 17α-(Butyryloxy)-9,11-didehydrodeoxycorticosterone; 17α-Butanoyloxy-21-hydroxypregna-4,9(11)-diene-3,20-dione |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H34O5 |
Molar mass | 414.542 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
- Clascoterone (cortexolone 17α-propionate; CB-03-01)
- List of steroidal antiandrogens
References
- Celasco G, Moroa L, Bozzella R, Ferraboschi P, Bartorelli L, Di Marco R, Quattrocchi C, Nicoletti F (2005). "Pharmacological profile of 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity". Arzneimittelforschung. 55 (10): 581–7. doi:10.1055/s-0031-1296908. PMID 16294504. S2CID 35386850.